WaveMan
WaveMan · Company
GUTS · Fractyl Health, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GUTS Fractyl Health (GUTS) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001572616
Quote by TradingView
Cluster · 5 insidersC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
30
13F, latest reported quarter

What the filings say about GUTS

Insiders, 180 days
+$167.1K net bought
5 buyers

Fractyl Health insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, FRACTYL HEALTH, INC. insiders bought a net $167.1K of stock across 23 Form 4 purchases and sales, with 5 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
BRADLEY WILLIAM
Director
BUY
2026-09-16 SECtraded 2026-09-14
64,516
$39.9K
-84.9%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 10, 2026.
  • +555.7% median (+555.7% mean) 90-day return after 2 previous buys.
  • The trade is 43.3% of the 149,138 shares held after it.
  • No other insider bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BRADLEY WILLIAM bought about $39.9K of GUTS on Sep 14, 2026; 30 funds added in the latest 13F quarter.
Royan Ajay
Director
BUY
2026-06-15 SECtraded 2026-06-12
23,000
$19.6K
+37.9%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 14, 2025.
  • +15.2% median (+15.2% mean) 90-day return after 2 previous buys.
  • The trade is 56.2% of the 40,901 shares held after it.
  • 4 other insiders bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Royan Ajay bought about $19.6K of GUTS on Jun 12, 2026; 4 other insiders bought within 30 days and 30 funds added in the latest 13F quarter.
BRADLEY WILLIAM
Director
BUY
2026-06-11 SECtraded 2026-06-10
68,493
$50.0K
+25.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 13, 2025.
  • The trade is 80.9% of the 84,622 shares held after it.
  • 4 other insiders bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BRADLEY WILLIAM bought about $50.0K of GUTS on Jun 10, 2026, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days and 30 funds added in the latest 13F quarter.
Sheffield Ian
Director
BUY
2026-06-11 SECtraded 2026-06-10
35,000
$25.6K
+25.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 35,000 shares held after it.
  • 4 other insiders bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sheffield Ian bought about $25.6K of GUTS on Jun 10, 2026, the largest insider purchase at the company since 2025; 4 other insiders bought within 30 days and 30 funds added in the latest 13F quarter.
Rajagopalan Harith
Chief Executive Officer
BUY
2026-06-11 SECtraded 2026-06-10
25,000
$18.2K
+25.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Dec 4, 2025.
  • The trade is 4.6% of the 540,557 shares held after it.
  • 4 other insiders bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Rajagopalan Harith bought about $18.2K of GUTS on Jun 10, 2026; 4 other insiders bought within 30 days and 30 funds added in the latest 13F quarter.
23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 18 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$167.1K over 180 days
+$39.9K over 90 days
more than 75% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
30 funds bought in last quarter
below 66% of Medical Devices
Revenue
-100.0% year over year
the lowest in Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
17.7% of the float short (float per yahoo 2026-10-26) · 1.2 days to cover · settled 2026-09-30
below 70% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch GUTS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-22.5%12M
-72%+118%+307%+496%2025-102025-122026-022026-042026-062026-082026-10 2026-06-10 · BRADLEY WILLIAM bought $50.0K2026-09-14 · BRADLEY WILLIAM bought $39.9K2026-06-10 · Sheffield Ian bought $25.6K2025-12-04 · Rajagopalan Harith bought $20.0K2026-06-12 · Royan Ajay bought $19.6K2026-06-10 · Rajagopalan Harith bought $18.2K2026-06-08 · Smith Weber Lara bought $13.8K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GUTS: institutional holders (13F)

13F holdings, latest reported quarter
Nantahala Capital Management, LLC
22,578,192 sh
$17.9M
Catalio Capital Management, LP
6,168,749 sh
$4.9M
VANGUARD CAPITAL MANAGEMENT LLC
6,096,926 sh
$4.8M
BANK OF AMERICA CORP /DE/
6,034,147 sh
$4.8M
Pale Fire Capital SE
5,003,237 sh
$4.0M

Congress trades in GUTS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GUTS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

GUTS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Goldman Sachs Absolute Return Tracker Fund
$118.9K position · as of 2026-06-30
0.0%
Victory Extended Market Index Fund
$10.3K position · as of 2026-07-31
0.0%
Fidelity Extended Market Index Fund
$479.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$991.3K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$84.4K position · as of 2026-05-31
0.0%
Blackstone Alternative Multi-Strategy Fund
$8.3K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
5 insiders reported buying shares.
The record shows a net $167.1K bought by insiders over 180 days, 30 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

GUTS financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$93.0K
four quarters, 2024-01-01 to 2024-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$83.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-146.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-161.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-48.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$0$93.0K$120.0K
Gross profitn/a$43.0K$43.0K
Operating income-$96.8M-$93.5M-$50.8M
Net income-$141.0M-$68.7M-$77.1M
EPS (diluted)-1.86-1.62-45.29
Operating cash flow-$90.3M-$65.5M-$42.8M
Cash$81.5M$67.5M$33.2M
SEC XBRL, fiscal years, as known on 2026-10-28

GUTS Stock Sonar score 5/7 axes

Find similar shapesCompare

GUTS ranks highest on insider conviction (85th percentile) and institutional and government (34th), and lowest on growth (1st), among Medical Devices peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
11
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-146.8% · 10 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-161.4% · 11 pct, sector of 188
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
85
Inputs
  • Net Form 4 buying (codes P and S), 180d$167K · 75 pct, sector of 140
  • Insider buyers, 180d5 · 94 pct, sector of 142
Institutional and government
34
Inputs
  • Funds adding, latest quarter30 · 34 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
21
Inputs
  • Short interest, % of float+17.7% · 7 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+13.7% · 35 pct, sector of 198
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GUTS filings, in plain words

Are Fractyl Health insiders buying or selling GUTS?

In the 180 days to 2026-10-28, Fractyl Health insiders were net buyers, a net $167.1K across purchases and sales reported on Form 4, by 5 buyers.

Read the full summary

In the 180 days to 2026-10-28, Fractyl Health insiders were net buyers of GUTS, a net $167.1K across purchases and sales reported on Form 4 by 5 buyers. 5 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies